Abstract
Pediatric intracranial sarcomas are rare, aggressive tumors with a poor prognosis in general. Here we report the case of a child who was initially diagnosed with a primary intracranial sarcoma, DICER1-mutant; subsequent genetic analyses confirmed a pathogenic germline DICER1 mutation. She received multimodal standard treatments consisting of surgery, radiotherapy and chemotherapy. The tumor recurred 2.5 years later within the surgical cavity. Following the gross tumor resection of this new lesion, the same multimodal standard approach was used. From a molecular perspective, evidence of hyperactivation of the MAPK-kinase pathway with a pathogenic KRAS mutation at both diagnosis and recurrence was present. The patient is currently in remission, 18 months post-end of treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Research data are stored in an institutional repository and will be shared upon request to the corresponding author.
References
Pelletier D, Rivera B, Fabian MR et al (2023) miRNA biogenesis and inherited disorders: clinico-molecular insights. Trends Genet 39(5):401–414
Koelsche C, Mynarek M, Schrimpf D et al (2018) Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathol 136(2):327–372
González IA, Stewart DR, Schultz KAP et al (2022) DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Mod Pathol 35(1):4–22
de Kock L, Wu MK, Foulkes WD (2019) Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes. Hum Mutat 40(11):1939–1953
de Kock L, Priest JR, Foulkes WD et al (2020) An update on the central nervous system manifestations of DICER1 syndrome. Acta Neuropathol 139(4):689–701
Maher OM, Khatua S, Mukherjee D et al (2016) Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature. J Neurooncol 127(1):155–163
Sakaguchi M, Nakano Y, Honda-Kitahara M et al (2019) Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant. Brain Tumor Pathol 36(4):174–182
Diaz Coronado RY, Mynarek M, Koelsche C et al (2022) Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer 128(4):697–707
Lafay-Cousin L, Lindzon G, Taylor MD et al (2016) Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. J Neurosurg Pediatr 17(3):298–302
Kosteniuk SE, Michaiel G, Dunham C (2023) A case of primary intracranial sarcoma, DICER1-Mutant, in a child with a germline DICER1 mutation. Brain Sci 13(7):1040
Vuong HG, Le MK, Dunn IF (2022) A systematic review of the clinicopathological features and prognostic outcomes of DICER1-mutant malignant brain neoplasms. J Neurosurg Pediatr 30(3):1–8
Schweizer L, Hartmann W, Koch A et al (2022) Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis. Neuropathol Appl Neurobiol 48(6):e12830
Funding
No funding was received for conducting this study.
Author information
Authors and Affiliations
Contributions
Conceptualization: A.L., S.R., V.L. Investigation: S.B.G, D.F, N.J., W.D.F., S.H., S.S., C.B., L.C., V.L., S.R. Writing (original draft): A.L., S.R. Writing (review and editing): all authors. Visualization: A.L., S.R. Supervision: S.R., V.L., N.J., W.D.F.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient and her family.
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lachance, A., Dimentberg, E., Huang, S. et al. Recurrent primary intracranial sarcoma, DICER1-mutant in a pediatric patient with DICER1 syndrome: the importance of molecular testing. Childs Nerv Syst 40, 1965–1969 (2024). https://doi.org/10.1007/s00381-024-06356-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-024-06356-1